Research Peptides
RESEARCH USE ONLY
Research Peptides
RESEARCH USE ONLY
| Ingredients | Acadesine (AICAR) — 5-aminoimidazole-4-carboxamide ribonucleotide, AMPK activator |
|---|---|
| Storage | Sealed, protected from light, store frozen at -20°C, avoid repeated freeze-thaw cycles |
| Shelf life | 24 months |
| SKU | Content - Spec | Pack | Price | Stock |
|---|---|---|---|---|
| AR50 | 50mg | 10 vials | $89.00 | In stock |
Research reagents are for laboratory and in-vitro research only. Not for human use.
Research reagents are not supplied as medicines and must not be used for diagnosis, treatment, prevention, clinical procedures or self-medication. Product information must not be used as administration or dosing guidance.
For accessories and consumables, follow their own specifications and documented intended use.
AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide), also known as Acadesine, is a synthetic AMP analog that acts as a potent activator of AMPK (AMP-activated protein kinase). It mimics low energy states in cells, promoting glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and endurance enhancement. AICAR is widely researched for its potential to improve metabolic function, fat loss, exercise performance, and insulin sensitivity. It is commonly referred to as “exercise in a pill” due to its ability to activate exercise-related metabolic pathways. It is typically used via injection in research settings and remains an investigational compound.
Activates AMPK and promotes fat oxidation; inhibits fatty acid synthesis; improves insulin sensitivity; increases glucose uptake; enhances mitochondrial function; reduces hepatic gluconeogenesis
The typical research dosage is 50-100 mg/kg/day by intraperitoneal injection, or by oral administration. Specific usage should be determined according to product specifications and professional guidance; consultation with a specialist in the relevant field is recommended.
Individuals seeking fat loss; patients with metabolic syndrome; adjunct support for type 2 diabetes (under research); athletes (note the possibility of banned substances)